Pancreatic Insufficiency (EPI) is a serious digestive problem and caused by
improper digestion, and exocrine pancreatic insufficiency. It is a kind of a
chronic disease caused by deficiency in pancreatic enzyme. Global
revenue of exocrine pancreatic insufficiency market, was valued at more than
USD 700 million in 2015, and is projected to surpass USD 1.2 Billion by 2023.
Furthermore, the global exocrine pancreatic market is anticipated to grow at a
CAGR between 8.0% – 8.6%. Increasing global incidences for exocrine
pancreatic insufficiency is one of the prime reasons increasing demand of
advanced therapeutics globally. Furthermore, presence of significant number of
pipeline drugs and lipase treatment in diabetic patients, optimizes the
chymotryps in and tryps in level are expected to drive the global market for
exocrine pancreatic insufficiency market over the forecast period.
discount for early purchase of “Global Exocrine
Pancreatic Insufficiency Market by region (North America, Europe,
Asia Pacific, Latin America and RoW)” report on
Moreover, the EPI Market has been segmented
by the mode of disease management, therapeutics drugs, diagnostic tests and
geography. Mode of disease management contains nutrition management, PERT.
Therapeutics drugs consist Creon, Zenpep, Pancreaze, Ultresa and Pertzye.
report covers the analysis of exocrine pancreatic insufficiency market by
therapeutics and diagnostic tests. Furthermore, the report covers the analysis
of global as well as regional markets of exocrine pancreatic insufficiency.
North America dominated the global market of exocrine pancreatic
insufficiency by accounting for the largest market share. While the Asia
Pacific region is expected to grow at a highest CAGR over the forecast period 2017–
2023. Moreover, the report provides deep insights on demand forecasts, market
trends and micro and macro indicators. In addition, this report provides
insights on the factors that are driving and restraining the demand globally as
well as regionally. Moreover, Infinium Global Research- Growth Matrix analysis
given in the report brings an insight on the investment areas that existing or
new market players can consider.
report provides insights into the market using analytical tools such as Porter’s
five forces analysis exocrine pancreatic insufficiency market. Moreover, the
study highlights current market trends and provides forecast from 2017 to 2023.
We also have highlighted future trends in the exocrine pancreatic insufficiency
market that will impact the demand during the forecast period. The Infinium
Global Research- Growth Matrix analysis provided in this report highlights key
investing markets in the world. Moreover, the competitive analysis given in
each regional market brings an insight on the market share of the leading
players. Additionally, the analysis highlights rise and fall in the market
shares of the key players in the market.
report on EPI market covers the companies such as Abbie, Inc., Allergan
plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx
Biopharma, Inc. MSD.